Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 5 selected

Guidance programme

Showing 11 to 20 of 981

TitleReference numberPublishedLast updated
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061

Results per page

  1. 10
  2. 25
  3. 50
  4. All